Clinical Edge Journal Scan

Multidisciplinary lifestyle program improves outcomes in RA


 

Key clinical point: “Plants for Joints” (PFJ), a 16-week multidisciplinary lifestyle program based on whole food plant-based diet, physical activity, and stress management in addition to usual care, significantly improved disease activity compared with usual care alone in patients with rheumatoid arthritis (RA) and low-to-moderate disease activity.

Major finding: After 16 weeks, patients receiving PFJ vs usual care alone had a greater reduction in disease activity score of 28 joints (DAS28; mean difference 0.90; P < .0001) and were more likely to achieve DAS28 <2.60 (odds ratio [OR] 4.6) and European Alliance of Associations for Rheumatology Good Response (OR 4.3; both P < .001). No serious adverse events were reported.

Study details: This randomized controlled trial, “Plants for Joints,” included 77 patients with RA and low-to-moderate disease activity who were randomly assigned to receive PFJ intervention plus usual care or usual care alone .

Disclosures: The trial was funded by Reade (The Netherlands) and other sources. The authors declared no conflicts of interest.

Source: Walrabenstein W et al. A multidisciplinary lifestyle program for rheumatoid arthritis: The “Plants for Joints” randomized controlled trial. Rheumatology (Oxford) . 2023 (Jan 6). Doi: 10.1093/rheumatology/keac693

Recommended Reading

Losing muscle mass tied to physical dysfunction in early RA
MDedge Rheumatology
Rituximab worsens COVID-19 outcomes in RA
MDedge Rheumatology
Commentary: Interstitial Lung Disease, Onset Time, and RA, January 2023
MDedge Rheumatology
Best estimates made for hydroxychloroquine retinopathy risk
MDedge Rheumatology
Teamwork guides cardio-rheumatology clinics that care for unique patient population
MDedge Rheumatology
Methotrexate use needs close monitoring in patients with RA of childbearing age
MDedge Rheumatology
Most patients successfully discontinue glucocorticoids after initiation as bridging therapy in RA
MDedge Rheumatology
Oral glucocorticoid use raises risk for Staphylococcus aureus bacteremia in RA
MDedge Rheumatology
Comorbidity burden tied to lower likelihood of achieving quality care in RA
MDedge Rheumatology
Tapering glucocorticoids to ≤2.5 mg/day increases the risk for flare in patients receiving bDMARD in RA
MDedge Rheumatology